Home » Canada Rejects Majority of New Drugs Based on Evaluations of Other HTAs
Canada Rejects Majority of New Drugs Based on Evaluations of Other HTAs
May 18, 2010
Drugmakers face an uphill battle gaining access to the Canadian market due largely to Canadian payers’ reliance on cost-benefit analyses performed by foreign health technology assessment (HTA) bodies, such as the UK’s National Institue for Health and Clinical Excellence (NICE), according to a pricing and reimbursement expert.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor